Aardens is a leading brand in the field of medical research and diagnostics, utilizing the latest technological breakthroughs to advance the realm of healthcare. With a mission to digitalize biology, Aardens transforms biology into data and data into biology. They offer comprehensive IT infrastructure for medical research, including genomics intelligence, machine learning technologies, and epidemic surveillance.

Aardens is dedicated to ethical patient enrollment methods, employing dynamic legal consent through smart contract technology. Their expertise extends to infection control, genomic material collection, AI-based medical screening, and genomics data sharing. Aardens is also committed to financial growth, utilizing its idle money for long-term value investments.

Privately owned, the company invests in large US and European companies, employing methods developed by renowned investors Benjamin Graham and Warren Buffett. In the near future, Aardens plans to introduce micro-investment opportunities for private investors. As GenTree's flagship project, Aardens provides complete technology infrastructure, dynamic patient consent methods, and cryptographic solutions for the GenTree Community Biobank.

With their cutting-edge technology and dedication to the advancement of medicine, Aardens is poised to become an industry standard in genomics research and development. Contact Aardens today to learn more about their innovative solutions and investment opportunities